Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | MYLK | Q15746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6532089 | 0.88 | TOP1 (0.39) | TOP1MPOXDHCHEK1CNR2 | |
| SCHEMBL6525537 | 0.75 | CASP3 (0.37) | CNR2 | |
| SCHEMBL6507186 | 0.74 | HTR2C (0.41) | TOP1CHEK1CNR2BACE1 | |
| SCHEMBL14538890 | 0.74 | GAA (0.41) | CNR2 | |
| SCHEMBL6514717 | 0.73 | PDE2A (0.44) | CHEK1 | |
| SCHEMBL6511094 | 0.72 | CHEK1 (0.41) | CHEK1CNR2 | |
| SCHEMBL6515376 | 0.72 | MAPT (0.41) | CHEK1CNR2 | |
| SCHEMBL6514701 | 0.72 | CHEK1 (0.36) | TOP1CHEK1CNR2BACE1 | |
| SCHEMBL6522000 | 0.71 | CHEK1 (0.41) | CHEK1CNR2 | |
| SCHEMBL6517699 | 0.71 | ATR (0.39) | CHEK1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | TOP1 979/4885MPO 4800/4885XDH 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.